A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics
Y Takei, K Kadomatsu, Y Yuzawa, S Matsuo… - Cancer research, 2004 - AACR
Y Takei, K Kadomatsu, Y Yuzawa, S Matsuo, T Muramatsu
Cancer research, 2004•AACRVascular endothelial growth factor (VEGF) plays a critical role during normal embryonic
angiogenesis and also in the pathological angiogenesis that occurs in a number of
diseases, including cancer. We developed a novel VEGF blockade system using RNA
interference. The small interfering RNA (siRNA) targeting human VEGF almost completely
inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the
control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically …
angiogenesis and also in the pathological angiogenesis that occurs in a number of
diseases, including cancer. We developed a novel VEGF blockade system using RNA
interference. The small interfering RNA (siRNA) targeting human VEGF almost completely
inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the
control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically …
Abstract
Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer. We developed a novel VEGF blockade system using RNA interference. The small interfering RNA (siRNA) targeting human VEGF almost completely inhibited the secretion of VEGF in a human prostate cancer cell line, PC-3, whereas the control scramble siRNA showed no effects. The VEGF siRNA with atelocollagen dramatically suppressed tumor angiogenesis and tumor growth in a PC-3 s.c. xenograft model. Atelocollagen provided a beneficial delivering means by which stabilization and efficient transfection of the siRNA injected into the tumors were achieved.
AACR